Tweets
Norwegian RevNatus Pregnancy study on 417 births in 350 women w/ axSpA: 86% (347) were breastfeeding @6wks, 70% @6mos, & 38% @12 mos. Non-breastfeeders more likely to have C-section (41 vs 20%), higher ASDAS-CRP (2.6 vs 2.2), CRP (5.3 vs 3.3), & VAS pain (41 vs 32) https://t.co/DI6owL5dof
Dr. John Cush @RheumNow ( View Tweet )
8 months 4 weeks ago
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not Sxs. https://t.co/Xsju7JdEVE
Dr. John Cush @RheumNow ( View Tweet )
8 months 4 weeks ago
Rheumatology: Believe It or Not (4/25/2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Should we believe the reviews and metanalyses?
https://t.co/pJFhcBkvjO https://t.co/9evGknrMSo
Dr. John Cush @RheumNow ( View Tweet )
8 months 4 weeks ago
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush @RheumNow ( View Tweet )
8 months 4 weeks ago
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush @RheumNow ( View Tweet )
8 months 4 weeks ago
Gout pts No-Shows after ED: Study of 159 gout pts w/ gout flare & ED visit - only 56 (35%) had an outpatient visit addressing gout within 6 mos. Higher odds w/ being married (OR 2.66), no comorbidities (OR 3.86), colchicine use (OR 2.7), being older (OR 1.44) https://t.co/tAorjwf8xX
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
US- Top Drug Rx Sales in 2024
Semaglutide $54 Billion
Tirzepatide $31.7 B
Adalimumab $28B
Apixaban $26 B
Empagliflozin $20.5 B
Pembrolizumab $18 B
Ustekinumab $17 B
Risankizumab $16 B
Dupilumab $15.6 B
Etanercept $10.1 B
Secukinumab $7.7 B
Immune globulin $7.1 B
Upadacitinib $7 https://t.co/Wjcu7LrTfC
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
RHEUMATOLOGIST SURVEY: Which Lupus patients should undergo renal Bx?
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
RHEUMATOLOGIST Survey: What are your contraindications tor renal Bx?
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
U.S. healthcare pharmaceutical spending reached $805.9 billion in 2024, a 10.2% increase from 2023 https://t.co/Aq7utEJ8sK https://t.co/zgEPppe6Oe
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush @RheumNow ( View Tweet )
9 months ago
Looking for the latest updates on treatments and disparities for patients with systemic lupus erythematosus and lupus nephritis?
Join us at AWIR 2025 to learn from Maria Dall’Era, MD, Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of https://t.co/QPyojkztCj
Association of Women in Rheumatology @AWIRGROUP ( View Tweet )
9 months ago
